

# Human Organ-specific Autoimmune Disease

## Molecular Cloning and Expression of an Autoantibody Gene Repertoire for a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ

Gregorio D. Chazenbalk, Stefano Portolano, Diego Russo, J. Scott Hutchison,\* Basil Rapoport, and Sandra McLachlan  
Thyroid Molecular Biology Unit, Veterans Affairs Medical Center, and University of California, San Francisco, California 94121; and  
\*Nichols Institute, San Juan Capistrano, California 92675

### Abstract

The most common organ-specific autoimmune disease in humans involves the thyroid. Autoantibodies against thyroid peroxidase (TPO) are present in the sera of virtually all patients with active disease. We report the molecular cloning of the genes for 30 high-affinity, IgG-class human autoantibodies to TPO from thyroid-infiltrating B cells. Analysis of the putative germline genes used for the TPO human autoantibodies suggests the use of only five different H and L chain combinations involving four H chains and three L chains. In addition, the same combination of H and L chains was found in multiple patients. The F(ab) proteins expressed by these genes define two major, closely associated domains (A and B) in an immunodominant region on TPO. These A and B domains contain the binding sites of ~ 80% of IgG-class TPO autoantibodies in the sera of patients with autoimmune thyroid disease. The present information permits analysis, not previously possible, of the relationship between autoantibody H and L chain genes and the antigenic domains on an autoantigen. Our data, obtained using target organ-derived autoantibodies, indicate that there is restriction in H and L chain usage in relation to the interaction with specific antigenic domains in human, organ-specific autoimmune disease. (*J. Clin. Invest.* 1993. 92:62-74.) **Key words:** autoantibody • autoantigen • autoimmunity • immunoglobulin gene • thyroid peroxidase

### Introduction

The most common organ-specific autoimmune disease in humans involves the thyroid. Hashimoto's thyroiditis and Graves' disease, in their pure forms, represent two ends of a clinical spectrum ranging from glandular hypofunction to hyperfunction. In both diseases there is a breakdown in tolerance to a number of thyroid-specific autoantigens and the generation of an IgG antibody response. Thyrotropin receptor autoantibodies occur predominantly in Graves' disease and are responsible for hyperthyroidism (reviewed in reference 1). Autoantibodies to thyroglobulin, of uncertain pathogenetic importance, tend to be found in patients with Hashimoto's thyroiditis rather than Graves' disease. However, autoantibod-

ies against thyroid peroxidase (TPO),<sup>1</sup> the cell surface enzyme responsible for thyroid hormone synthesis and previously known as the thyroid "microsomal" antigen, are present in virtually all patients with active autoimmune thyroid disease (2, 3).

TPO autoantibodies are of high affinity and predominantly IgG1 and IgG4 (4). There is evidence that these IgG1 (but not IgG4) autoantibodies may play a role in thyroid cell destruction (reviewed in reference 5). TPO autoantibodies correlate well with thyroid inflammation in autopsy studies of subjects without clinical thyroid disease (6). With newer, sensitive assays, TPO autoantibodies (of unknown affinity) are detectable, usually at low levels, in up to 25% of the adult female population (7). The present concept is that autoimmune thyroid disease is predominantly subclinical because of sufficient thyroid reserve and regeneration under the influence of thyrotropin.

Information on the genes coding for organ-specific autoantibodies, as well as knowledge of their epitopes, would be invaluable in understanding the pathogenesis of antibody-mediated autoimmune diseases. Among the major organ-specific human autoimmune diseases (thyroiditis, diabetes mellitus type I, pemphigus vulgaris, myasthenia gravis, primary biliary cirrhosis, pernicious anemia, and Addison's disease), few IgG class monoclonal autoantibodies have been produced and even fewer cloned at the molecular level (8-12). In no disease have both the autoantibody repertoire and the autoantigenic domains been defined.

We now report the molecular cloning of the genes for 30 new organ-specific (TPO) human autoantibodies. These genes all code for high-affinity IgG autoantibodies. We demonstrate that these TPO autoantibodies, which appear to utilize a restricted number of H and L chain genes, encompass a restricted immunodominant region on TPO recognized by patients with autoimmune thyroid disease.

### Methods

**Molecular cloning of TPO-binding F(ab) fragments.** In order to obtain TPO-binding F(ab)s we used thyroid tissue from patients with autoimmune thyroid disease because it is enriched, compared with blood, lymph node, and thymus, in B cells secreting TPO autoantibodies (reviewed in reference 13). In addition, previous studies have demonstrated the difficulty of obtaining thyroid-specific monoclonal autoantibodies, particularly TPO autoantibodies, by using blood versus thyroid lymphocytes (14).

We constructed five new human F(ab) combinatorial cDNA libraries from the thyroid tissue of three patients (WR, TR, and JA) with Graves' disease in the vector Immunozap (Stratagene, La Jolla, CA) as described previously (10), with the following modifications. We pre-

Dr. Russo's present address is University of Reggio Calabria, Catanzaro, Italy.

Address reprint requests to Dr. McLachlan, Thyroid Molecular Biology Unit (111T), Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121.

Received for publication 13 October 1992 and in revised form 8 January 1993.

Table I. Oligonucleotide Primers Used to Amplify the H and L ( $\kappa$ ) Chain Genes

Primer	Sequence	Source	Family/C region
<b>VH region primers</b>			
1a	5'-CAG GTG CAG <u>CTC</u> <u>GAG</u> CAG TCT GGG-3'	(16)	VH1; plus others
3a	G- - - - - G- - - - - (C- - - - - G C- - - - -) (G- - - - - G C- - - - - GG)	(16) VH1/5BACK (17) VH3BACK (17)	VH3; plus others VH1; VH5 VH3
VH2	5'-CAG GTC AAC <u>CTC</u> <u>GAG</u> GAG TCT GG-3' (- - - - - G C- - - - -)	based on (17) VH2BACK (17)	VH2 VH2
VH6	5'-CAG GTA CAG <u>CTC</u> <u>GAG</u> CAG TCA GG-3' (- - - - - G C- - - - -)	based on (17) VH6BACK (17)	VH6 VH6
1f	5'-CAG GTG CAG CTG <u>CTC</u> <u>GAG</u> TCT GGG-3'	(16)	VH1; VH4
3f	G- - - - - G- - - - - (- - - - - A- - - - - G - -)	(16) VH4BACK (17)	VH3; plus others VH4
VHc	5'-AG GTG CAA CTG <u>CTC</u> <u>GAG</u> TCT GG-3'	Immunozap	unspecified
VHd	- - - - - G - -	Immunozap	unspecified
<b>H chain constant region primers</b>			
CH1	5'-AGC ATC <u>ACT</u> <u>AGT</u> ACA AGA TTT GGG CTC-3'	Immunozap	IgG hinge region
C $\tau$ 4	5'-GCA TGA <u>ACT</u> <u>AGT</u> TGG GGG ACC ATA TTT GGA-3'	(18)	IgG4 hinge region
<b>V<math>\kappa</math> primer</b>			
V(L)k	5'-GT GCC AGA TGT <u>GAG</u> <u>CTC</u> GTG ATG ACC CAG TCT CCA (- - C A - - A - C - C - - - - -) (- - A A - T - A - C - C - - G - - - - -)	(45) VK1a (16) VK3a (16)	Family crosspriming
<b><math>\kappa</math> constant region primer</b>			
C(L)k	5'-T CCT <u>TCT</u> <u>AGA</u> CTA ACA CTC TCC CCT GTT GAA GCT CTT TGT GAC GGG CGA ACT C-3'	Immunozap	

Included in parentheses (for comparison) are primers used in other studies. VH families for which the primers were designed are indicated. Dashes indicate identity. Nucleotide restriction sites are underlined; XhoI, SpeI, SacI, and XbaI for VH, CH, V(L)k, and C(L)k regions, respectively.

pared cDNA by reverse transcription (First Strand Synthesis kit; Stratagene) of mRNA obtained either by the technique of Han et al. (15) or using the QuickPrep mRNA purification kit (Pharmacia, Inc., Piscataway NJ). In an attempt to cover as wide a range of heavy chain variable region (VH) genes as possible, we used upstream primers described by Persson et al. (16), primers of Marks et al. (17) modified by introducing restriction sites, as well as the VHc and VHd region primers of Stratagene (Table I). Two heavy (H) chain libraries were constructed from each of the WR and JA cDNA, one using the "CH1" constant region primer of Stratagene and the other using an IgG4 constant region primer (C $\tau$ 4) based on nucleotide sequence data in the IgG4 hinge region (18) (Table I). PCR conditions were as follows: 25 cycles at 94°C for 1 min, 54°C for 1 min, 72°C for 1 min; and 15 cycles at 94°C for 1 min, 54°C for 1 min, and 72°C for 2 min. These diverse primers all produced VH products of the correct size (Fig. 1). Because TPO autoantibodies are predominantly of  $\kappa$  L chain type (4), we used the Immunozap V(L) $\kappa$  and C(L) $\kappa$  primers (Table I).

The unamplified combinatorial libraries ( $0.8\text{--}2.0 \times 10^6$  recombinants) were screened in XL1-Blue cells by conventional techniques (19) using as antigen the secreted, recombinant human TPO (20) labeled with  $^{125}\text{I}$  to a specific activity of  $10\text{--}20 \mu\text{Ci}/\mu\text{g}$  protein by the iodogen method (21). TPO-binding plaques were cloned to homogeneity and plasmids were excised from the Immunozap bacteriophage using the helper phage R408, according to the Stratagene protocol. Nucleotide sequencing of the cDNA inserts was performed by the dideoxynucleotide chain termination method (22).

**Preparation of soluble F(ab) fragments.** F(ab)s were expressed as soluble proteins in XL1-Blue cells, as previously described (11). In brief, protein synthesis was induced with 1 mM isopropyl-thio-galactopyranoside (Sigma Chemical Co., St. Louis, MO) for 2 h at 37°C. The cells were then pelleted, resuspended in 0.02 times the original volume

of 10 mM Tris, pH 8.0, containing  $2 \mu\text{g}/\text{ml}$  aprotinin,  $1 \mu\text{g}/\text{ml}$  leupeptin,  $1 \mu\text{g}/\text{ml}$  pepstatin,  $0.1 \text{ mM}$  phenylmethylsulfonyl fluoride (all from Sigma Chemical Co.). After one freeze-thaw, the suspension was sonicated, membranes pelleted by centrifugation at  $4,000 g$  and the F(ab)s were affinity-purified from the supernatant using a Protein G sepharose column (Pharmacia, Inc.).

**Direct F(ab) binding of  $^{125}\text{I}$ -TPO.** As previously described (11), F(ab)s diluted in assay buffer ( $0.1 \text{ M}$  NaCl,  $10 \text{ mM}$  Tris-HCl, pH 7.5,  $0.1\%$  Tween 20, and  $0.5\%$  BSA) were incubated with  $^{125}\text{I}$ -TPO ( $15,000\text{--}20,000 \text{ cpm}$ ) and mouse monoclonal antibody to human  $\kappa$  light chains (QE11, Recognition Sciences, Birmingham, UK) in a total




Figure 1. VH gene products generated by the PCR in a representative experiment. PCR conditions were as described in Methods using the following oligonucleotides in conjunction with the CH1 primer (Table I): lane 1, VH6; lane 2, VH2; lane 3, VHc/d; lane 4, VH1a/3a; lane 5, VH1f/3f; lane 6, PM2 marker digested with Hind III.

volume of 200  $\mu$ l. After 1 h at room temperature, 100  $\mu$ l of donkey anti-mouse Sac-cel (IDS, Boldon, Tyne and Wear, UK) was added, and the incubation was continued for 30 min. After addition of 1 ml of assay buffer and vortexing, the mixture was centrifuged for 5 min at 1,000  $g$  to sediment the immune complexes which were then counted to determine the percent radiolabeled TPO bound. The affinities of the F(ab)s for TPO were determined by Scatchard analysis (23) from values obtained in the presence of increasing concentrations of unlabeled TPO.

**Competition between F(ab)s for binding to TPO.** One F(ab) was immobilized by incubation (total volume of 200  $\mu$ l) with murine mAb anti-human  $\kappa$  (QE11) for 1 h at room temperature. After incubation with 100  $\mu$ l of Sac-cel (30 min at room temperature), the immobilized F(ab) complexes were diluted in assay buffer (see above) and centrifuged at 1,000  $g$  (5 min at 4°C). The pellets were resuspended in normal human serum diluted 1:30 in assay buffer to saturate remaining anti- $\kappa$  binding sites. In a separate set of tubes, increasing concentrations of "free" F(ab) were preincubated with  $^{125}$ I-TPO for 1 h at room temperature. Aliquots (100  $\mu$ l) were then incubated for 30 min with the immobilized F(ab) pellets and washed with assay buffer, and the radioactivity bound to the Sac-cel was counted. Nonspecific binding ( $\sim$  2% of total counts added) was subtracted to provide values for specific binding to TPO.

**Competition studies between F(ab) fragments and serum TPO autoantibodies.** Sera from 10 patients with autoimmune thyroid disease were studied. All sera contained high levels of TPO autoantibodies (detectable by ELISA [24] at dilutions of 1:1,000 or greater). Binding of  $^{125}$ I-TPO by serum autoantibodies was measured by precipitating the antigen-antibody complex with Protein A (Pansorbin, Calbiochem-Behring Corp., La Jolla, CA) (2) in the presence of increasing concentrations of F(ab) fragments. The F(ab) fragment-TPO complex, lacking the CH2 domain of the Fc region, is not precipitated by Protein A. Use of Protein A is effective for serum TPO autoantibodies (2) because of the near absence of IgG3 TPO autoantibodies (4, 25).

Duplicate aliquots of sera were incubated for 1 h at room temperature with  $^{125}$ I-TPO, alone or with F(ab) fragments. Pansorbin (100  $\mu$ l) was added and the incubation was continued for 30 min. After addition

of 1 ml assay buffer (see above), the mixture was vortexed and centrifuged for 30 min at 1,000  $g$  (4°C), supernatants were removed by aspiration, and TPO remaining in the pellets was counted. In preliminary experiments, we determined serum dilutions needed to provide binding values of 15–20% in the absence of F(ab) fragments. These dilutions ranged from 1:1,000 to 1:7,000. Nonspecific  $^{125}$ I-TPO binding in the presence of control serum without TPO antibodies was 2–5% of total cpm added. This value was subtracted from the values obtained with patients' sera in calculating the percent inhibition by the F(ab) fragments.

## Results

**Frequencies and subclass of TPO-specific F(ab)s.** Screening 5 F(ab) combinatorial libraries from three patients (WR, TR, and JA) yielded 30 TPO-binding clones which were plaque-purified. The frequencies of TPO-binding F(ab)s (Table II) differed markedly between patients. Far more TPO-specific F(ab)s were obtained from patients TR and WR than from patients SP and JA. These frequencies refer only to TPO-binding F(ab)s and are *not* a measure of the frequency of the individual VH and VL chains in the libraries.

For two patients, two different libraries were prepared. The WR I, TR I, JA I, and the previously reported (10) SP I libraries used the "CH1" primer (Stratagene) which we subsequently observed crossprimed for both IgG1 and IgG4 (26). The WR IV and JA IV libraries used an IgG4 specific primer (Table I). Both IgG1 and IgG4 F(ab)s were isolated from the WR I and SP I libraries, whereas only IgG4 F(ab)s were obtained from the WR IV library and at a higher frequency. In contrast, the TR I library yielded only IgG1 F(ab)s. The large number of TPO-specific IgG4 F(ab)s obtained from the WR I library and the lack of such F(ab)s from the TR I library is consistent with the greater contribution of IgG4 to TPO autoantibodies in the serum of patient WR relative to patient TR (data not shown).

Table II. Summary of TPO-specific Human F(ab)s Obtained from Four Graves' Patients

Library (frequency)*	Subclass	Clone	H chain			L chain		
			Germline <sup>‡</sup>	VH	JH	Germline <sup>‡</sup>	VK	JK
WR I (10/90,000)	1	1.7; 1.9	V1-3b	1	4	KL012	1	1
	4	4.2–5; 4.8	HV1L1	1	4	KL012	1	2
		4.10; 4.12						
WR IV (12/30,000)	4	4.21; 4.22; 4.25–35	HV1L1	1	4	KL012	1	2
TR I (7/90,000)	1	1.3; 1.5	8-1B	3	4	KL012	1	2
	1	1.6; 1.8	HV1263	1	3	A3	2	2
	1	1.9; 1.13	V1-3b	1	4	A'	1	4
	1	1.10	V1-3b	1	4	KL012	1	1
JA I (1/200,000)	1	1.9	HV1L1	1	6	KL012	1	4
JA IV (0/200,000)	—	—						
SP I <sup>§</sup> (3/180,000)	1	1.2	HV1L1	1	6	KL012	1	2
		1.4; 1.5	HV1L1	1	6	KL012	1	1
	4	4.6	HV1L1	1	4	KL012	1	2

Combinatorial libraries were constructed from mRNA prepared from intrathyroidal B cells (Methods). \* Frequency of TPO-specific clones.

<sup>‡</sup> Putative germline genes based on data presently available. <sup>§</sup> Previously published (11). Clone SP4.6 was obtained by recombining the SP1.2 L chain with the parent SP I H chain library (26).

A

																										CDR1					
		D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	
KLO12		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	CGG	GCA	AGT	CAG	AGC	ATT	
WR4.2		.G	C..	GT.						.T							.G				.T						.T			.A	
WR4.35		.G	C..	GT.														.G				.T					.T			.A	
WR4.4		.G	C..	GT.													.T	.G			.A	.T								G..	
WR4.12		.G	C..	GT.												.C	.T	.G			.A	.T								G..	
WR4.10		.G	C..	GT.										.T				.G		.C		.T								.C	
WR4.36		.G	C..	GT.													.G	.G				.T								.C	
WR4.33		.G	C..	GT.													.G	.G				.T								.G	
WR4.21		.G	C..	GT.													.G	.G				.T								.C	
WR4.22		.G	C..	GT.													.G	.G				.T								.C	
WR4.32		.G	C..	GT.													.G	.G				.T								.C	
WR4.8		.G	C..	GT.								.G					.G	.G				.T								.C	
WR4.3		.G	C..	GT.													.G		.C			.T								.C	
WR4.37		.G	C..	GTC													.G		.C			.T								G..C	
WR4.25		.G	C..	GT.													.C	.G				.T								G..C	
JAL.9		.G	C..	GT.													.C														
SP1.5		.G	C..	GT.																										.A	
SP1.4		.G	C..	GT.													.G													.C	
TR1.5		.G	C..	GT.														.C								.C					
WR1.9		.G	C..	GT.																										.A	
WR1.7		.G	C..	GT.																										.A	
SP1.2		.G	C..	GT.						.T							.AG			.C								G..	.AT		
TR1.3		.G		GT.													.C													.C	
TR1.10		.G		GT.								.T	C.											.A							

																										CDR2					
		S	S	Y	L	N	W	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	A	A	S	S	L	Q	S			
KLO12		AGC	AGC	TAT	TTA	AAT	TGG	TAT	CAG	CAG	AAA	CCA	GGG	AAA	GCC	CCT	AAG	CTC	CTG	ATC	TAT	GCT	GCA	TCC	AGT	TTG	CAA	AGT			
WR4.2		.T	CAA								.G					.G	.A				.C		.A			.C		.T			
WR4.35		.T	CAA		C.						.G					.G	.A				.C		.A			.A		.T			
WR4.4		G.T	C.								.TG					.G	.A				.C		.A				.T				
WR4.12		G.T	C.								.TG										.C		.A				.T				
WR4.10		G.T	C.		C.						.G	G.	.A			.A	G.				.C		.A			.A		GT.			
WR4.36		G.T	C.		C.						.G	G.				.A	.A				.C		.A			.A		GT.			
WR4.33		GTT	CA.		C.						.G	G.				.A	.A				.C		.A			.A		GT.			
WR4.21		G.T	C.		C.						.G	G.G		.T		.A	.A				.C		.A			.A		GT.	G.		
WR4.22		G.T	C.		C.						.G	G.				.A	.A				.C		.A			.A		GT.	G.		
WR4.32		G.T	C.		C.						.G	G.				.A	.A				.C		.A			.A		GT.	G.A		
WR4.8		G.T	C.		C.						.G	G.		.G		.A	.A				.C		.A	G		.A		GT.	G.		
WR4.3		G.T	C.		C.			.C			.G	G.				.A	.A				.C		.A			.A		GT.			
WR4.37		G.T	C.		C.						.G	G.				.A	.A				.C		.A			.A		GT.			
WR4.25		G.T	C.G		C.				.A		.G	.T	.G			.A	.A				.C		.A			GA		TT			
JAL.9			.G						.A																						
SP1.5		G..	.AA						.G		.G						G.				.A			.A			.C				
SP1.4		G..	.C.							.A							.A			.C			.A				.C				
TR1.5		.A.																								.C	.A	.TT			
WR1.9		G..	.G															G.			.C		.A			.T		.TG			
WR1.7		G..	.G						.A									G.			G.	.C		.A			.C		.TG		
SP1.2			.G		.C						.C						.A				.C					.C	.A				
TR1.3		G..	GA.	.C						.G	.T		.T			.C			G.		.C					.A	.A	.C	.C		
TR1.10		.C.	.AA			GC.					.A			.A	G.		.C	.A			.T			.A	T.		.C			G..	

**TPO-specific F(ab) gene usage.** The nucleotide sequences (Figs. 2 and 3) and derived amino acid sequences (Figs. 4 and 5) of the 30 new and 4 previously reported TPO-specific F(ab)s from patient SP (10, 11, 26) were compared to the closest, presently known germline genes. It must be emphasized that, even with the recent expansion of VH germline sequence information (27), the germline assignments are putative and cannot be regarded as definitive without characterization of the respective genes in these patients. Homologies are shown simply as a means to categorize the large body of data.

The 34 TPO human autoantibodies appeared to use a relatively restricted number and combination of H and L chain genes (Figs. 2–5, summarized in Table II). In particular, L chain putative germline gene KL012 (28), a VK1, is used in TPO autoantibodies from all four patients (Figs. 2 and 4). In three patients, KL012 was the only L chain obtained. However, for this very large group of L chains, the possibility of other germline gene usage cannot be excluded. Indeed the nucleotide sequence pattern (Fig. 2) of the WR4 L chains differs from

those of the other KL012-related L chains. In one patient (TR), two other TPO-specific L chains were obtained; A' (29) is a VK1 (like KL012) and A3 (29) is a VK2.

The TPO-specific F(ab) H usage appears to be slightly less restricted than that of the L chain (Figs. 3 and 5, summarized in Table II). Four different groups of H chains were used, involving three VH1 and one VH3 germline genes. One group of H chains related to HV1L1 (30) was used in three patients and another smaller group similar to V1-3b (31) was used in two patients. Both H chains are members of the VH1 family and are used in combination with putative L chain germline genes KL012 or A'. Two of the TPO-specific H chains, related to the VH3 gene 8-1B (32) and the VH1 gene HV1263 (33), were found in a single patient. One of these H chains, related to 8-1B, was found in combination with a KL012-like L chain. Out of a total of five H and L chain combinations, only one was unique for both H and L chains (HV1263/A3). The D regions could not be clearly assigned to any known germline sequences.

## B

	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y
KL012	GGG	GTC	CCA	TCA	AGG	TTC	AGT	GGC	ACT	GGA	TCT	GGG	ACA	GAT	TTC	ACT	CTC	ACC	ATC	AGC	AGT	CTG	CAA	CCT	GAA	GAT	TTT	GCA	ACT	TAC
WR4.2	...	...	...	...	...	...	...	...	TC.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	GT.	...	
WR4.35	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	T.	...
WR4.4	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.12	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.10	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.36	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.33	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.21	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.22	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.32	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.8	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.3	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.37	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.25	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
JA1.9	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
SP1.5	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
SP1.4	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
TR1.5	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR1.9	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR1.7	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
SP1.2	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
TR1.3	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
TR1.10	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...

			CDR3						
	Y	C	Q	Q	S	Y	S	T	P
KL012	TAC	TGT	CAA	CAG	AGT	TAC	AGT	ACC	GCT
WR4.2	...	...	...	...	...	..T.	...	..G	...
WR4.35	...	...	...	...	...	..T.	...	..G	...
WR4.4	...	...	...	...	..T.	..C.	...	..G	...
WR4.12	...	...	...	...	..T.	..C.	...	..G	...
WR4.10	...	...	..A.	..C.	..T.	..CA	...	..G	...
WR4.36	...	...	..A.	...	...	..CA	...	..G	...
WR4.33	...	...	..A.	...	...	..CA	...	..G	...
WR4.21	...	...	...	...	...	..CA	..G	...	...
WR4.22	...	...	...	...	...	..CA	..G	...	...
WR4.32	...	...	...	...	...	..CA	..G	...	...
WR4.8	...	...	...	...	...	..CA	..G	...	...
WR4.3	...	...	..A.	...	...	..CA	..G	..G	...
WR4.37	...	...	..A.	...	...	..CA	..G	..G	...
WR4.25	...	...	..A.	...	..T.	..CA	...	...	...
JA1.9	...	...	...	...	...	..A.	...	...	...
SP1.5	...	...	...	...	...	...	...	..G	...
SP1.4	...	...	...	...	...	...	...	..G	...
TR1.5	...	...	...	...	..C.	..G	..G	...	...
WR1.9	...	...	..C	...	GA.	...	..G	...	...
WR1.7	...	...	..G.	...	GA.	...	..G	...	...
SP1.2	...	...	..C.	...	..T.	..G	...	...	...
TR1.3	...	...	...	...	GC.	...	..G	...	...
TR1.10	C..	...	..G	...	GC.	...	..G	---	...

Figure 2. Nucleotide sequences of TPO-specific F(ab) L chains. Designation of the framework (FR) and CDRs and the JK germline genes are according to Kabat et al. (29). The sources of the closest currently known VK germline genes are KL012 (28) and A' and A3 (29). Sequences with identical nucleotides or silent substitutions were as follows: WR4.35–WR4.5; WR4.32–WR4.31; WR4.8–WR4.2/28.34. The nucleotide sequences shown here and in Fig. 3 have been submitted to GenBank (Accession No. L12061–L12103).

The large group of F(ab)s which are most closely related to the germline gene HV1L1 require further comment because they appear to fall into two groups. The WR4 clones and SP4.6 are of subclass IgG4 while SP1.2 and JA1.9 are of subclass IgG1 (Table II). There are consistent nucleotide (Fig. 3) and amino acid (Fig. 5) differences in the framework and complementarity determining regions (CDRs), which suggest that these two groups may not be derived from the same VH germline genes. Although HV1L1 is the closest available germline gene currently available, it may not be the precursor of either group of F(ab)s. Finally, the D and J regions of the two F(ab) groups are different. It should be stressed that each of these unique VH, D, and J combinations was obtained from combinatorial libraries prepared from three different patients.

**F(ab) affinities for TPO.** We expressed recombinant F(ab)s representative of the different H and L chain permutations (Table III). Despite the use of multiple bacterial hosts and culture conditions, only small amounts (up to ~ 40 µg purified protein per liter) of purified protein could be obtained. Nevertheless, this amount was sufficient for further studies.

Calculation of the affinities ( $K_d$ ) for human TPO revealed all F(ab)s to bind with high affinity (~  $10^{-10}$  M) (Table III), comparable to autoantibodies in patients' sera (2).

**Domains on TPO recognized by F(ab)s.** Competition between pairs of F(ab)s for binding to human TPO was used to define their respective binding domains. In this approach, increasing concentrations of one F(ab) were preincubated with radiolabeled TPO and then added to a second, immobilized F(ab). Representative experiments are shown in Fig. 6. For example (Fig. 6 A), TR1.8 and TR1.9 each completely inhibited TPO binding to immobilized TR1.9. In contrast, preincubation of WR1.7 and SP1.5 with radiolabeled TPO did not prevent subsequent TPO binding to immobilized TR1.9. Despite these differences in their ability to compete for TPO binding to TR1.9, all free F(ab)s were capable of binding comparable amounts of radiolabeled TPO in separate, concurrent direct binding assays (Fig. 6 B).

The above experiment (Fig. 6, A and B) demonstrates overlap in the areas on TPO recognized by TR1.9 and TR1.8 but not between TR1.9 and WR1.7 or SP1.5. Similarly, there was

**A**

	Q	V	Q	L	V	-	Q	S	G	A	E	V	N	K	P	G	A	S	V	K	V	S	C	K	A	S	G	D	T	F
HV1L1	CAG	GTG	CAG	CTG	GTG	---	CAG	TCT	GGG	GCT	GAG	GTG	AAC	AAG	CCT	GGG	GCC	TCA	GTG	AAG	GTG	TCC	TGC	AAG	GCT	TCT	GGA	GAC	ACC	TTC
JA1.9	...	...	A.A	...	C.C	GAG	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
SP1.2	...	...	A.A	...	C.C	---	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
SP4.6	...	...	A.A	...	C.C	---	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.2	...	...	A.A	...	C.C	---	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.34	...	...	A.A	...	C.C	---	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.32	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.35	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.27	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.10	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.12	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.25	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.28	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
WR4.31	...	...	A.A	...	C.C	GAG	G.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...

		CDR1										CDR2																
	T	G	Y	Y	M	H	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	W	I	N	P	N	S	G	
<b>HV1L1</b>	ACC	GGC	TAC	TAT	ATG	CAC	TGG	GTG	CGA	CAG	GCC	CCT	GGA	CAA	GGG	CTT	GAG	TGG	ATG	GGA	TGG	ATC	AAC	CCT	AAC	AGT	GGT	
JA1.9	...	...	C.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	A	...	...	...	G.	...	...	A	...
SP1.2	...	...	C.	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	A	...	...	...	G.	...	...	A	...
SP4.6	.A.	.A.	...	C.	G.T	...	...	...	...	...	...	...	...	...	...	...	...	...	...	G.	...	...	...	...	...	...	A	...
WR4.2	.G.	.A.	...	C.	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.34	.G.	.A.	...	...	.T	...	...	...	...	...	...	...	...	G	...	C	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.32	.G.	.A.	...	...	.T	...	...	...	...	...	...	...	...	G	C.	G.	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.35	...	.A.	...	...	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.27	.G.	.A.	...	C.	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.10	.A.	.A.	.T.	...	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.12	.A.	.A.	.T.	...	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.25	.A.	.A.	...	...	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.28	.A.	.A.	...	...	.T	...	...	...	...	...	...	G.	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.
WR4.31	.A.	.A.	...	...	.T	...	...	...	...	...	...	...	...	G	...	...	...	...	G.	...	...	...	...	...	...	G	A.	.C.

	CDR2																													
	G	T	N	Y	A	Q	K	F	Q	G	R	V	T	M	T	R	D	T	S	I	S	T	A	Y	M	E	L	S	R	
HV1L1	GGC	ACA	AAC	TAT	GCA	CAG	AAG	TTT	CAG	GGC	AGG	GTC	ACC	ATG	ACC	AGG	GAC	ACG	TCC	ATC	AGC	ACA	GCC	TAC	ATG	GAG	CTG	AGC	AGG	
JA1.9	.C.	...	.GG	.T.	...	...	...	...	...	...	...	...	...	...	...	.C	...	...	...	.T	.A.	...	.T.	...	...	...	...	...	G.C	
SP1.2	.C.	...	.GG	.T.	...	...	...	...	...	...	...	...	...	...	...	.C	...	...	...	.T	.A.	...	.T.	...	...	...	...	...	G.C	
SP4.6	...	.G	.GA	...	T.C	...	...	...	...	...	...	...	...	...	...	.A	...	...	G.	...	...	G.	...	.T	...	...	...	.C.	.C	
WR4.2	...	.G	.GA	...	T.	G.	...	...	...	...	...	...	...	...	...	...	...	...	G.	...	...	G.	...	.T.	...	...	G.	.C.	.C	
WR4.34	...	.G	.GA	...	T.	G.	...	...	...	...	.A	...	...	...	...	...	...	...	G.	...	...	G.	...	.T.	...	...	...	.C.	.C	
WR4.32	...	.G	.GA	...	T.	G.	...	...	...	...	...	...	...	...	...	...	...	...	G.	...	...	G.	...	.T.	...	...	...	.C.	.C	
WR4.35	...	.G	.GA	...	T.	G.	...	...	...	...	...	...	...	...	...	...	...	...	G.	...	...	G.	...	.T.	...	...	.A	...	.C.	.C
WR4.27	...	.G	.GA	T.	T.	G.	.G	...	...	...	C.	...	...	...	...	C.	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	
WR4.10	...	.G	.GA	T.	T.	G.	.G	...	...	...	G.C	...	...	...	...	C.	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	
WR4.12	...	.G	.GA	T.	T.	G.	.G	...	...	...	C.	...	...	...	...	C.	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	
WR4.25	...	.G	.GA	T.	T.	G.	.G	...	...	.C.	G.	...	...	...	...	G.	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	
WR4.28	...	.G	.GA	T.	T.	G.	...	...	...	...	C.	...	...	...	...	...	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	
WR4.31	...	.G	.GA	T.	T.	G.	...	...	...	...	C.A	...	...	...	...	...	...	...	G.	...	...	G.	A.	...	...	...	...	.C.	.C	

	L	R	S	D	D	T	A	V	Y	Y	C	A	-
HV1L1	CTG	AGA	TCT	GAC	GAC	ACG	GCC	GTG	TAT	TAC	TGT	GCG	---
JA1.9	...	...	.T.	...	...	...	...	...	...	...	.T.	...	ACA
SP1.2	...	...	.T.	...	...	...	...	...	...	...	...	...	ACA
SP4.6	...	.A.	.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.2	...	.A.	.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.34	...	.AG	.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.32	...	.A.	.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.35	...	.A.	.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.27	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.10	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.12	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.25	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.28	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA
WR4.31	...	.A.	G.G	...	...	...	...	...	...	...	.C	.C	CGA

Figure 3. Nucleotide sequences of TPO-specific F(ab) H chains. Designation of the FR and CDRs is according to Tomlinson et al. (27). The sources of the closest, presently known VH germline genes are HV1L1 (30), HV1263 (33), V1-3b (31), and 8-1B (32). SP4.6 is a F(ab) obtained recently from patient SP (26). Sequences with identical nucleotides or silent substitutions were as follows: WR4.2–WR4.3, 4, 5, 8, 11, 21, 22, 33, 36, 37 with the exception that WR4.3, 5 and 8 have CAG, not GAG at codon 7; SP1.2–SP1.4, 5 (11); TR1.9–TR1.13.

overlap in the WR1.7 binding domain with those of TR1.8 and SP1.5 but not with TR1.9 (Fig. 6 C). The SP1.5 binding domain overlapped that of TR1.3 and WR1.7 but not TR1.9 (Fig. 6 D). The SP1.5 domain appeared to overlap to a small extent with that of TR1.8 (Fig. 6 D). It is important to note that these differences between F(ab) binding domains are not related to differences in their affinities for TPO (Table III).

The above competition studies and others not shown, cover-

ing all permutations of immobilized and free F(ab)s, suggest that there are two domains, A and B, recognized on human TPO. The extent to which the F(ab)s interact with each domain is summarized in Table IV and is shown schematically in Fig. 7. The binding sites of SP1.5 and WR4.5 lie completely within the TPO A domain. TR1.9 binds entirely to the B domain. TR1.8 interacts predominantly with the B domain but overlaps slightly with the A domain. Conversely, WR1.7 binds

# B

	Q	V	Q	L	V	-	Q	S	G	A	E	V	K	K	P	G	A	S	V	K	V	S	C	K	A	S	G	Y	T	F
<u>V1-3b</u>	CAG	GTC	CAG	CTG	GTG	---	CAG	TCT	GGG	GCT	GAG	GTG	AAG	AAG	CCT	GGG	GCC	TCA	GTG	AAG	GTT	TCC	TGC	AAG	GCT	TCT	GGA	TAC	ACC	TTC
TR1.10	...	..G	A.A	...	C.C	GAG	...	..A	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	..TT	...	
TR1.9	...	..G	A.A	...	C.C	GAG	...	..A	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	..G	...	
WR1.7	...	..G	A.A	...	C.C	GAG	...	..A	...	...	..A	A.A	...	...	..C	...	...	...	..A	C	...	...	...	G	...	...	...	G	...	
WR1.9	...	..G	A.A	...	C.C	GAG	...	..T	...	...	..A	A.A	...	...	...	...	...	...	..CA	C	...	...	...	G	...	...	...	G	...	

		<u>CDR1</u>																						<u>CDR2</u>					
	T	S	Y	A	M	H		W	V	R	Q	A	P	G	Q	R	L	E	W	M	G		W	I	N	A	G	N	G
<u>V1-3b</u>	ACT	AGC	TAT	GCT	ATG	CAT		TGG	GTG	CGC	CAG	GCC	CCC	GGA	CAA	AGG	CTT	GAG	TGG	ATG	GGA		TGG	ATC	AAC	GCT	GGC	AAT	GGT
TR1.10	...	..C	...	CA	T	T		...	...	...	...	...	...	...	...	..T	...	...	...	...	...		...	...	C	...	..A	...	
TR1.9	...	..T	...	..G	C	A		...	...	...	...	...	...	...	...	...	...	...	...	...	...		...	...	..G	...	..C	..A	
WR1.7	...	..AT	...	ATG	TA	...		...	...	...	...	...	...	..G	...	...	...	...	...	...	...		...	...	..A	...	..A	..A	
WR1.9	...	..AT	...	ATG	TA	...		...	...	...	...	...	...	..G	...	...	...	...	...	...	...		...	...	..A	...	..A	..A	

		<u>CDR2</u>																												
	N	T	K	Y	S	Q	K	F	Q	G		R	V	T	I	T	R	D	T	S	A	S	T	A	Y	M	E	L	S	S
<u>V1-3b</u>	AAC	ACA	AAA	TAT	TCA	CAG	AAG	TTC	CAG	GGC		AGA	GTC	ACC	ATT	ACC	AGG	GAC	ACA	TCC	GCG	AGC	ACA	GCC	TAC	ATG	GAG	CTG	AGG	AGC
TR1.10	...	...	...	...	...	...	...	...	...	...		...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
TR1.9	...	...	...	...	...	...	...	..T	..G	...		...	...	...	..T	...	...	...	...	...	...	..C	...	...	...	..G	...	...	...	...
WR1.7	..G	..T	..G	..C	...	...	...	...	...	...		...	...	...	..G	..A	...	...	...	...	...	...	T	...	...	..A	...	...	...	...
WR1.9	..G	..T	..G	...	...	...	...	...	...	...		...	...	...	..G	..A	...	...	...	...	...	...	T	...	...	..A	...	...	...	...

	L	R	S	E	D	T	A	V	Y	Y	C	A	R																	
<u>V1-3b</u>	CTG	AGA	TCT	GAA	GAC	ACG	GCT	GTG	TAT	TAC	TGT	GCG	AGA																	
TR1.10	...	...	...	...	...	...	...	...	...	...	...	...	...																	
TR1.9	...	...	C	...	...	...	...	...	...	...	...	...	...																	
WR1.7	...	..C	...	...	...	...	..A	...	..T	...	..T	...	...																	
WR1.9	...	..C	...	...	...	...	..A	...	..T	...	..T	...	...																	

	GTC	CTA	GGG	ATA	ATT	GCA	GCT	GAC	CAC																				
	GAC	CCG	TAT	GGT	GGG	GGC	AAG	TCA	GAG																				
	CGG	GGA	GAC	AGC	AAC	ATC	TGG	TAT	CTC	GGC																			
	CGG	GGA	GAC	AGC	AAC	ATC	TGG	TAT	CTC	GGC																			

# C

	E	V	Q	L	V	-	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	F	T	V
<u>8-1B</u>	GAG	GTG	CAG	CTG	GTG	---	GAG	TCT	GGG	GGA	GGC	TTG	GTC	CAG	CCT	GGG	GGG	TCC	CTG	AGA	CTC	TCC	TGT	GCA	GCC	TCT	GGA	TTC	ACC	GTC
TR1.3	C	...	A.A	...	C.C	GAG	...	..A	...	..A	...	A	...	...	...	...	...	...	...	...	...	...	..T	..T	..G	...	..G	..A	...	
TR1.5	C	...	A.A	...	C.C	GAG	...	..A	...	..C	...	...	...	...	...	...	...	...	...	...	...	...	..T	...	..G	...	C	..AT	...	

	S	S	N	Y	M	S		W	V	R	Q	A	P	G	K	G	L	E	W	V	S		V	I	Y	S	G	G	S
<u>8-1B</u>	AGT	AGC	AAC	TAC	ATG	AGC		TGG	GTC	CGC	CAG	GCT	CCA	GGG	AAG	GGG	CTG	GAG	TGG	GTC	TCA		GTT	ATT	TAT	AGC	GGT	GGT	AGC
TR1.3	..AA	CT	...	...	..C	...		...	...	...	...	...	...	...	...	...	...	...	...	...	...		...	..T	..C	..AC	..A	..AT	
TR1.5	..AA	CT	...	...	..C	...		...	...	...	...	...	...	...	...	...	...	...	...	...	...		...	..C	..T	..C	..AC	...	..C

	T	Y	Y	A	D	S	V	K	G		R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	S	L
<u>8-1B</u>	ACA	TAC	TAC	GCA	GAC	TCC	GTG	AAG	GGC		AGA	TTC	ACC	ATC	TCC	AGA	GAC	AAT	TCC	AAG	AAC	ACG	CTG	TAT	CTT	CAA	ATG	AAC	AGC	CTG
TR1.3	C	..T	..T	...	...	...	..G	...	...		C	G	...	C	...	...	...	...	...	...	...	...	G	A	...	...	...	...	...	
TR1.5	...	..T	...	...	...	...	...	...	...		C	...	...	...	...	...	...	...	...	...	...	...	G	A	...	...	...	...	...	

	R	A	E	D	T	A	V	Y	Y	C	A	R																	
<u>8-1B</u>	AGA	GCC	GAG	GAC	ACG	GCT	GTG	TAT	TAC	TGT	GCG	AGA																	
TR1.3	...	...	...	...	..C	..C	...	...	...	...	..A	...																	
TR1.5	..C	...	..C	...	..C	C	T	...	...	...	..AG	...																	

	ACT	CAG	GGC	ACC	AGA	AGT	TAT	TAC																					
	T	...	...	...	...	...	..C	...																					

	Q	V	Q	L	V	-	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	G	T	F
<u>HV1263</u>	CAG	GTC	CAG	CTG	GTG	---	CAG	TCT	GGG	GCT	GAG	GTG	AAG	AAG	CCT	GGG	TCC	TCG	GTG	AAG	GTC	TCC	TGC	AAG	GCT	TCT	GGA	GGC	ACC	TTC
TR1.6	...	..G	A.A	...	C.C	GAG	...	..A	...	...	...	...	...	...	...	...	...	...	...	...	...	...	..G	...	...	...	...	...	...	
TR1.8	...	..G	A.A	...	C.C	GAG	...	..A	...	..G	...	...	...	...	...	...	...	...	...	...	...	..C	..GA	...	...	..G	..A	..C	...	...

	S	S	Y	A	I	S		W	V	R	Q	A	P	G	Q	G	L	E	W	M	G		R	I	I	P	I	L	G
<u>HV1263</u>	AGC	AGC	TAT	GCT	ATC	AGC		TGG	GTG	CGA	CAG	GCC	CCT	GGA	CAA	GGG	CTT	GAG	TGG	ATG	GGA		AGG	ATC	ATC	CCT	ATC	CTT	GGT
TR1.6	..A	..AG	..T	...	..CA	...		...	..A	...	...	...	..A	...	...	...	...	...	...	...	...		..G	..A	..T	...	..G	..T	..G
TR1.8	..AA	..A	..T	..A	...	...		...	..G	...	...	...	...	...	...	...	...	...	...	...	..C		..G	..T	...	..G	..T	...	

	I	A	N	Y	A	Q	K	F	Q	G		R	V	T	I	T	A	D	K	S	T	S	T	A	Y	M	E	L	S	S
<u>HV1263</u>	ATA	GCA	AAC	TAC	GCA	CAG	AAG	TTC	CAG	GGC		AGA	GTC	ACG	ATT	ACC	GCG	GAC	AAA	TCC	ACG	AGC	ACA	GCC	TAC	ATG	GAG	CTG	AGC	AGC
TR1.6	..C	..A	...	...	...	...	...	...	...	...		...	...	...	..T	...	...	...	..G	...	...	...	..T	...	...	...	..G	...	...	
TR1.8	GC	..A	..T	...	...	..T	...	..A	...	...		..A	...	..A	...	...	...	...	...	...	...	..A	..T	...	...	..C	..T	..AT	..C	

	L	R	S	E	D	T	A	V	Y	Y	C	A	R																
<u>HV1263</u>	CTG	AGA	TCT	GAG	GAC	ACG	GCC																						

	FR1	CDR1	FR2	CDR2	FR3	CDR3	JKappa
<b>KL012</b>	DIVMTQSPSSLSASVGRVTITC	RASQSISSYLN	WYQKPGKAPKLLIY	AASSLQS	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	QQSYSTP	
TR1.10	EL.....P.....N.	.....TK..A	.....E.....	DS.T..G	.....V.....T.....H.	..A.T..-	1
JA1.9	EL.....P.....R.....	.....R.....	.....E.....	.....E.....	.....A.....I.....	.....N.....	4
SP1.4	EL.....TVGT.....	.....TVGT.....	.....E.....	T.T.T..	.....R.....	.....T.....	2
TR1.5	EL.....N.....	.....N.....	.....E.....	T.L.	.....H.....N.....	.....A.....	2
TR1.3	EL.....T.GD.....	.....T.GD.....	.....D.S..P..V..	..N.HT	.....H.....	.....A.....	1
SP1.5	EL.....S.....	.....N.GK.....	.....R.....E.....	GT.T..	.....E.....V.....	.....D.....	2
WR1.9	EL.....GR.....	.....GR.....	.....V..H	T..L	.....E.....V.....	.....D.....	1
WR1.7	EL.....N.GR.....	.....N.GR.....	.....V.VH	T.T.L.	.....T.....V.....	..G.D..	1
WR4.2	EL.....Q.....	.....Q.....	.....S.....	T.T.L.	.....S.....V.....	..I.....	2
WR4.35a	EL.....Q.....H	.....Q.....H	.....S.....	T.N.L.	.....T.....S.....I.....	..I.....	2
WR4.33	EL.....MVH..H	.....MVH..H	.....A.....S	T.N.V.	.....T.E..S.....R.....	..T.....	2
WR4.12	EL.....L..I.....	.....VGR.....	.....M.....S	T..L.	.....T.E..S.....	..FT..	2
WR4.4	EL.....I.....	.....VGR.....	.....M.....S	T..L.	.....T.E..S.....	..FT..	2
WR4.25	EL.....VGR..H	.....VGR..H	.....K..E..S	T.D.L.	.....T.E..S.....S.....	..FT..	2
WR4.3	EL.....T.....	.....GR..H	.....H.A..S	T.N.V.	.....T.E..S.....	..T.....	2
WR4.37	EL.....T.....	.....VGR..H	.....A.....S	T.N.V.	.....T.E..S.....G.....	..T.....	2
WR4.32b	EL.....GR..H	.....GR..H	.....A.....S	T.N.VG	.....T.E..S.....	..T.....	2
WR4.22	EL.....GR..H	.....GR..H	.....A.....S	T.N.VG	.....T.E..S.....	..T.....	2
WR4.8c	EL.....GR..H	.....GR..H	.....A.R..S	T.N.VG	.....T.E..S.....	..T.....	2
WR4.36	EL.....GR..H	.....GR..H	.....A.....S	T.N.VG	.....T.E..S.....	..T.....	2
WR4.21	EL.....GR..H	.....GR..H	.....A.N..S	T.N.VG	.....T.E..S.....	..T.....	2
WR4.10	EL.....L.....S	.....GR..H	.....A..E..S	T.N.V	.....T.E..S.I.....	..FT..	2
SP1.2	EL.....E..T.....	.....EN..R.S.	.....Q.....S	..T.....	.....H.....N.....	..T..S.	2
<b>A'</b>	AIQLTQSPSSLSASVGRVTITC	RASQGISSALA	WYQKPGKAPKLLIY	DASSLES	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	QQFNSYP	
TR1.13	ELVM.....	.....RG..	.....R.....	..T.....	.....S.....	.....	4
TR1.9	ELVM.....N.A.	.....R.....	.....R.....	..N.....	.....I.....	.....	4
<b>A3</b>	DIVMTQSPSLPVTGEPASIS	RSSQLLHNSGYNLYD	WYLQKPGQSPQLLIY	LGSNRAS	GVPDFRSGSGSGTDFTLKISRVEAEDVGVYYC	MQALQTP	
TR1.6	EL.....G.....	.....G.....	.....S.....	.....S.....	.....P.....	.....P.....	2
TR1.8	EL.....F.....	.....G.....	.....S.....	.....S.....	.....P.....	.....P.....	2

Figure 4. Derived amino acid sequences of TPO-specific F(ab) L chains. Designation of the FR and CDRs and sources of VK germline genes are as in Fig. 2. (a) Same as WR4.5; (b) same as WR4.31; (c) Same as WR4.27, 28, 34.

primarily to the A domain but also overlaps with TR1.8 (but not TR1.9) in the B domain. The binding site of TR1.3 spans the A and B domains equally.

*Domains on TPO recognized by autoantibodies in patients' sera.* The question arises as to what extent the TPO binding domains A and B reflect the binding domains of TPO autoantibodies in patients' sera. F(ab)s WR1.7 and TR1.9 were se-

lected for competition studies with serum TPO autoantibodies because their binding sites do not overlap yet extensively cover the A and B domains.

A spectrum of competition patterns was observed in 10 randomly selected sera of patients with autoimmune thyroid disease. In the representative examples shown, TPO autoantibodies in patients' sera were inhibited preferentially by WR1.7

	FR1	CDR1	FR2	CDR2	FR3	CDR3 (D)	
<b>HV111</b>	QVQLV-QSGAEVVKPGASVKSCASGDTFT	GYMH	WVRQAPGQGLEWMG	WINPNSGGTNYAQKFQG	RVTMTDTSISTAYMELSLRSDTAVYYCAR		
WR4.10	..K.LEE...LK.....YN.N	DF.I.	.....V	.....KNA..RFSE..	G.....A..AT...TS..A.....F..	GLGVGTWGL	JH4
WR4.12	..K.L.E...LK.....YN.N	DF.I.	.....V	.....KNA..RFSE..	G.....A..AT...TS..A.....F..	.....	
WR4.28	..K.L.E...LK.....YN.N	D.I.	.....A.....V	.....KNA..RFSE..	G.....A..AT...TS..A.....F..	.....I.....	
WR4.27	..K.L.E...LK.....R..V..Y..S	D.HI.	.....V	.....KNA..RFSE..	G.....A..AT...TS..A.....F..	.....	
WR4.34	..K.L.E...LK.....R..P..Y..S	D.I.	.....V	.....KNA..R.SE..	G.....A..AV...TS.....	.....V.....	
WR4.35	..K.L.E...LK.....R..Y..T	D.I.	.....V	.....KNA..R.SE..	G.....A..AV...TS.....	.....V.....	
WR4.32	..K.L.E...LK.....R..P..Y..S	D.I.	.....AV..V	.....KNA..R.SE..	G.....A..AV...TS.....	..VP.....	
WR4.31	..K.L.E...LK.....R..YN.N	D.I.	.....V	.....KNA..RFSE..	G.....A..AT...TS..A.....H..	..V.....	
WR4.25	..K.L.E...LK.....R..Y..N	D.I.	.....V	.....KNA..RFSE..A	G.....G..A..AT...TS..A.....F..	.....	
WR4.2 <sup>a</sup>	..K.L.E...LK.....R..V..Y..S	D.HI.	.....V	.....KNA..R.SE..	G.....A..AV...VTS.....	..V.....	
SP4.6	..K.L.E...LKN.....R..Y..N	D.HV.	.....V	.....KNA..R.SQ..	G.....A..A...TS..K.....	..V.....	
JA1.9	..K.LEE...K.....Y.....	..H..	.....I	..S..R.A.RF.....	.....S..N.V...G..F.....T	TRTA	JH6
SP1.2 <sup>b</sup>	..K.L...K.....Y.....	..H..	.....I	..S..R.A.RF.....	.....S..N.V...G..F...F..T	.....	
<b>V1-3b</b>	QVQLV-QSGAEVVKPGASVKSCASGYTFT	SYAMH	WVRQAPGQGLEWMG	WINAGNCTKYSQKFQG	RVTITDTSASTAYMELSLRSEDVAVYYCAR		
WR1.7	..K.LE...I.....L..E..D...	N.MI.	.....	.....D..KIR.....	.....S.....T.....S	RGDSNIWYLG	JH4
WR1.9	..K.LE...I.....TL..E..D...	N.MI.	.....	.....D..KIR.....	.....S.....T.....S	.....	
TR1.9 <sup>c</sup>	..K.LE...S.....	..GL.	.....	..S..T.....R.	..F.....T..G...P.....	DPYGGGKSE	
TR1.10	..K.LE...I.....	..HL.	Y.....S.....	..P.K.....	.....L.MN.....	VLGIIAADH	
<b>8-1B</b>	EVQLV-ESGGGLVPGGSLRLSCAASGFTV	SSNYM	SWVRQAPGQGLEWV	SVIYSGSTYYADSVK	GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR		
TR1.3	Q.K.LE...I.....VV..LN.	KL...	T.....	..FTD.NP.....R	.....L.....E..V.....	TQGTSSYY	JH4
TR1.5	Q.K.L...IH.....V..LN.	KL...	T.....	..TFTD.T.F.....	.....D..I.....T.D..L..K	S.....	
<b>HV1263</b>	QVQLV-QSGAEVVKPGSSVKVSCASGDTF	SSYAI	SWVRQAPGQGLEW	MGRIPILGIANYAQKF	QGRVTITADKSTSTAYMELSLRSEDVAVYYCAR		
TR1.6	..K.LE...R.....	NKF..	H..I.....	..GF..MF..TT.....	.....S.....V...V...A..I...T	GNDRGPVASFG	JH3
TR1.8	..K.LE...R.....RT.....	NKF..	.....R.....	..GF..MF..ATY.....	..K.....NI...D.NT..T.....T	A...AY.....	

Figure 5. Derived amino acid sequences of TPO-specific F(ab) H chains. Designation of the FR and CDRs and sources of the VH germline genes are as in Fig. 3. SP4.6 is a F(ab) obtained recently from patient SP (26). The Q to K substitution at position 3 represents the restriction site introduced by the PCR oligonucleotide. The presence of an E at position 6 (not in the putative germline gene) results from the use of the 1a/3a oligonucleotide primers (see Table I). (a) Same as WR4.3, 4, 5, 8, 11, 21, 22, 33, 36, 37 with the exception that WR4.3, 5, and 8 have Q (for E) at position 7; (b) same as SP1.4, 5 (11); (c) Same as TR1.13.






Figure 6. Domains on TPO recognized by F(ab)s. Increasing concentrations of one F(ab) were preincubated with radiolabeled TPO and then added to a second, immobilized F(ab) (Methods). The immobilized F(ab) was TR1.9 (panel A), WR1.7 (panel C), and SP1.5 (panel D). Confirmation of the direct binding potency of the free F(ab)s was determined concurrently in each experiment. A representative control (panel B for the experiment in panel A) is shown.

(Fig. 8 A), preferentially by TR1.9 (Fig. 8 B) or in a more balanced proportion by both F(ab)s (Fig. 8 C). Overall, of the 10 sera, five were inhibited preferentially by WR1.7, two by TR1.9, and three to approximately the same extent by WR1.7 and TR1.9.

Of greater importance was the efficacy of the combination of the WR1.7 and TR1.9 F(ab)s in competing for serum TPO autoantibody binding. In the 10 sera, this combination inhibited TPO autoantibody binding by  $83 \pm 5\%$  (mean  $\pm$  SEM). These figures may underestimate the full extent of the inhibition because of limitations to the highest concentrations of F(ab)s which could be used for competition.

## Discussion

There is evidence that the ability to produce TPO autoantibodies is inherited as an autosomal dominant trait in women with

incomplete penetrance in men (34, 35). The location and nature of the gene or gene cluster responsible for this inheritance are unknown. Polymorphisms at the VH locus are associated with autoantibody production (31, 36). Therefore, knowledge of the genetic background of TPO-specific autoantibodies may provide insight into the basis for the inheritance of thyroid autoimmunity.

The present report identifies and characterizes the genes coding for a comprehensive panel of high-affinity human autoantibodies to a major, organ-specific autoantigen. These recombinant F(ab)s cover a region on thyroid peroxidase recognized by a majority ( $\sim 80\%$ ) of autoantibodies in the sera of patients with thyroiditis, the most common autoimmune disease. In the more intensively studied connective tissue diseases, genes for numerous autoantibodies have been characterized. Initially, the "natural" and disease-associated autoantibodies cloned were IgM, many of low affinity and with polyspecificity (37,

Table III. Affinities for Human TPO of Expressed F(ab) Fragments

H chain	L chain	Clone	Affinity $K_d$ (M)
HV1L1	KL012	WR4.5	$3.0; 3.2 \times 10^{-10}$
		SP1.2*	$8.0 \pm 1.0 \times 10^{-11}$
		SP1.4*	$2.0; 2.0 \times 10^{-10}$
		SP1.5*	$8.0 \pm 1.0 \times 10^{-11}$
		SP4.6*	$1.0 \pm 0.2 \times 10^{-10}$
V1-3b	KL012	WR1.7	$1.2; 2.9 \times 10^{-10}$
		TR1.10	$1.7; 1.4 \times 10^{-10}$
8-1B	KL012	TR1.3	$5.1 \pm 0.1 \times 10^{-10}$
HV1263	A3	TR1.8	$2.7 \pm 0.1 \times 10^{-10}$
V1-3b	A'	TR1.9	$1.5 \pm 0.2 \times 10^{-10}$

Classification is according to their putative germline genes based on presently available data. Values from duplicate or triplicate experiments were calculated by Scatchard analysis (23). \* Previously reported (11, 26).

38). More recently, high-affinity IgG-class rheumatoid factors and antibodies to double-stranded DNA have been produced and defined (39–42). However, the combination of a comprehensive autoantibody repertoire and its antigenic domain(s) has not been defined previously in either organ-specific or non-organ-specific autoimmune disease in humans.

From thyroid tissue-infiltrating B cells from three patients with autoimmune thyroiditis, we have cloned and determined the nucleotide sequences of 30 new TPO-specific F(ab)s. Previously, we had reported information on four antibodies obtained from another patient (10, 11, 26). The most remarkable finding from analysis of the putative germline genes used for TPO human autoantibodies is the relatively restricted number and combinations of H and L chain genes. Similarly, there is evidence for restricted T cell receptor V gene usage in the early stages of autoimmune thyroid disease (reviewed in reference 43). In our study of 34 recombinant F(ab)s, we found a total of only five different H and L chain combinations involving four H chains and three L chains. In addition, one combination of H and L chains (HV1L1 and KL012) was obtained

Table IV. Domains on TPO Recognized by F(ab)s as Determined by Competition between Pairs of F(ab)s for Antigen Binding

Clone	TPO domains		H chain	L chain
	A	B		
SP1.5	++++	—	HV1L1	KL012
WR4.5	++++	—	HV1L1	KL012
WR1.7	++++	++	V1-3b	KL012
TR1.3	++++	++++	8-1B	KL012
TR1.8	+	++++	HV1263	A3
TR1.9	—	++++	V1-3b	A'

Classification is according to their putative germline genes based on presently available data. +++++, complete; —, no overlap with the indicated domain. + or ++, partial overlap.





Figure 7. Schematic representation of the binding domains on TPO for the expressed F(ab)s.

from combinatorial libraries prepared from three patients. Another H and L chain combination (V1-3b and KL012) was found in libraries prepared from two patients. These combinations involved different H chains (HV1L1 and V1-3b) with the same L chain (KL012). As stated previously, these apparent H and L chain restrictions are based on presently available information on germline genes in the population. Without data on the germline genes in the individual patients, it is possible, particularly for the L chains, that additional germline genes may be involved.

Studies of “natural” autoantibodies and autoantibodies to erythrocyte antigens have shown over-representation of VH4 family genes (38, 44). In contrast, four-fifths of our TPO-specific F(ab) combinations were derived from VH1 family germline genes. The other F(ab) utilized a VH3 germline gene. Among the VH1-encoded TPO F(ab)s, the most abundant were related to the recently described HV1L1 germline gene, which is utilized in a rheumatoid factor (30). Because of the pattern of nucleotide differences between our TPO F(ab)s and HV1L1, it is possible that the former are not derived from HV1L1 but from another, as yet undescribed, germline gene.

Three factors could contribute to the apparent TPO-specific VH and VL gene restriction that we observed: (a) the use of thyroid-infiltrating B cells, (b) limitations imposed by the oligonucleotide primers used in the PCR, and (c) overrepresentation of particular VH and VL genes in our libraries. First, regarding the source of the B cells, our panel of TPO-specific F(ab)s was only obtained because we used lymphocytes from the thyroid, which is enriched with TPO-specific B cells (reviewed in reference 13). Information on TPO autoantibodies generated from extrathyroidal sources would be of interest but would be beyond the scope of the present study. Further, this goal may not be feasible given the statistics of the H and L chain combinatorial approach and the ethical impossibility of boosting our patients with TPO, as was done with tetanus toxoid (16, 45).

It is unlikely that the TPO-specific F(ab) H and L chain gene restriction can be attributed to limitations in the oligonucleotide primers used in the study. In the case of the H chains, we used a wide range of variable region primers designed to



**Figure 8.** Domains on TPO recognized by autoantibodies in three representative sera (panels *A*, *B*, and *C*) from patients with autoimmune thyroid disease. F(ab)s WR1.7 and TR1.9, alone or in combination, were used to compete for serum autoantibody binding to radiolabeled TPO (Methods).

cover all six VH families (Table I). In addition, the F(ab)s obtained used variable regions genes from more than one VH (VH1, VH3) and VK (VK1, VK2) family. Our libraries also contain VH4 genes as we obtained this family in a F(ab), the sequence of which is not included in the results because we could not express the protein.

We have evidence against the possibility of over-representation in our libraries of particular VH and VL genes. In separate studies (26), we observed that functional HV1L1 VH and KL012 VL genes in a library are relatively rare,  $\sim 1:5,000$  and  $1:500$ , respectively. Finally, the most important evidence suggesting that the TPO-specific VH and VL gene restriction observed is not a consequence of all three potential limitations discussed above is that the F(ab)s expressed in our repertoire represent more than 80% of TPO autoantibodies present in patients' sera.

Whether or not the combinatorial library approach can generate the H and L chain combinations observed *in vivo* is under debate (46, 47). The same pairing of H and L chains was observed in murine monoclonal antibodies (specific for influenza hemagglutinin) generated by both conventional hybridoma technology and the combinatorial recombinant F(ab) approach (48). In contrast, in a study of hapten antibodies, the *in vivo* H and L chain pairing was not attained by the combinatorial approach (46). In addition, some studies have shown H chain promiscuity in pairing with L chains (47). Therefore, we cannot be certain that the TPO-specific H and L chain combinations reflect the *in vivo* situation. However, using a TPO-specific H (or L) chain to randomly search for other L (or H) chains from the same patient capable of forming F(ab)s with high affinity for TPO, we did not observe promiscuity and only obtained closely related L and H chains from the same VK and VH families (26). Further, our F(ab)s had very high affinities for TPO ( $\sim 10^{-10}$  M), comparable with those of serum TPO autoantibodies (2).

Turning to the other major aspect of our study, the majority of TPO autoantibodies in patients' sera interact with the protein in its native, undenatured state (11, 49, 50). Despite studies using different approaches (reviewed in reference 5),

the number of epitopes recognized by TPO autoantibodies, or even the number of antigenic domains involved, was unknown. Previous evidence, with which the present data are in agreement, suggested that the human autoimmune response to TPO (51, 52), like that to thyroglobulin (53), is limited to a few epitopic domains.

Using a comprehensive repertoire of recombinant human F(ab)s, we now define two major contiguous epitopic areas, A and B, on TPO. Most IgG-class serum TPO autoantibodies interact with the A and B domains. TPO is a large (933 amino acids, 107 kD) (54) globular protein relative to the size of the F(ab) binding site (55). For this reason and because a combination of only two different F(ab)s can compete for binding by most TPO autoantibodies, the autoimmunogenic region comprises a single, relatively small area (domains A + B). It is possible that serum TPO autoantibodies to other regions of TPO, including linear epitopes (reviewed in reference 5), exist but these will comprise a small proportion of the repertoire (11, 56).

The present information now permits analysis of the relationship between H and L chain genes and the antigenic domains on TPO recognized by TPO autoantibodies. Such an analysis has not previously been possible in an autoimmune disease. The clearest association is between the L chain gene KL012 and the A domain on TPO (Table IV). In contrast, the B domain is most closely associated with the L chains A' and A3. The H chains are more diverse and may alter the fine specificity of the F(ab) binding site by interacting with antigenic areas adjacent to the L chain binding site. In some instances, exemplified by TR1.3 (VH 8-1b/VK KL012), the H chain appears to shift the F(ab) binding from the A domain to cover both A and B domains.

Of interest is the observation that F(ab)s of both subclass IgG1 and IgG4 can interact with the A domain on TPO. All of the IgG4 and some of the IgG1 F(ab)s appear to be related to the VHI germline gene HV1L1. Use of the same VH germline gene by F(ab)s of two IgG subclasses raises the possibility of subclass switching. In rheumatoid factors, the same germline gene has clearly been shown to code for a low-affinity IgM and

subsequently for an affinity-matured IgG molecule (42). In contrast, observations of crossreactive idiotypes in human antibodies to *Haemophilus influenzae* b polysaccharide indicate independent B cell lineages in IgG1 and IgG2 antibodies (57). However, in the case of the TPO-specific IgG1 and IgG4 F(ab)s, we feel that subclass switching is unlikely. First, there are significant differences between the VH1 components of the IgG subclasses. Second, these H chains have totally different D and J regions.

Studies in mice have provided evidence for (58–60) and against (61) restricted H and L chain usage in rheumatoid factors and DNA autoantibodies. Similarly, a diverse array of immunoglobulin genes occurs in human rheumatoid factors derived from rheumatoid synovial tissue (62). A possible explanation for these divergent observations is that the autoantibodies are interacting with a wide range of epitopes. For example, thyroglobulin autoantibodies, induced by immunization in mice, interact with many epitopes and are derived from a large number of V region gene segments (63). In contrast, our data in an organ-specific autoimmune disease, indicate that disease-associated autoantibodies recognize a limited antigenic region on TPO. Such autoantibodies do, indeed, appear to be associated with restricted H and L chain usage.

## Acknowledgments

We thank Dr. Orlo Clark and Dr. Quan Duh (University of California, San Francisco) and Dr. Sebastiano Filetti (University of Catanzaro, Italy) for providing the Graves' thyroid tissue used in this study.

This research was supported by National Institutes of Health grants DK-36182 and EY-09498.

*Note Added in Proof.* We note the recent report by Hexham et al. (1992. *Autoimmunity*. 14:169–172) of the H and L chain variable region sequences of a human monoclonal TPO autoantibody generated by fusion of Hashimoto thyroid lymphocytes with a mouse myeloma line.

## References

- Nagayama, Y., and B. Rapoport. 1992. The thyrotropin receptor twenty-five years after its discovery: new insights following its molecular cloning. *Mol. Endocrinol.* 6:145–156.
- Beever, K., J. Bradbury, D. Phillips, S. M. McLachlan, C. Pegg, A. Goral, W. Overbeck, G. Feifel, and B. Rees Smith. 1989. Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. *Clin. Chem.* 35:1949–1954.
- Doullay, F., J. Ruf, J.-L. Codaccioni, and P. Carayon. 1991. Prevalence of autoantibodies to thyroperoxidase in patients with various thyroid and autoimmune diseases. *Autoimmunity*. 9:237–244.
- Parkes, A. B., S. M. McLachlan, P. Bird, and B. Rees Smith. 1984. The distribution of microsomal and thyroglobulin antibody activity among the IgG subclasses. *Clin. Exp. Immunol.* 57:239–243.
- McLachlan, S. M., and B. Rapoport. 1992. The molecular biology of thyroid peroxidase: cloning, expression and role as autoantigen in autoimmune thyroid disease. *Endocr. Rev.* 13:192–206.
- Yoshida, H., N. Amino, K. Yagawa, K. Uemura, M. Satoh, K. Miyai, and Y. Kumahara. 1978. Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. *J. Clin. Endocrinol. Metab.* 46:859–862.
- Prentice, L. M., D. I. W. Phillips, D. Sarsero, K. Beever, S. M. McLachlan, and B. Rees Smith. 1990. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. *Acta Endocrinol.* 123:493–498.
- Pascual, V., and J. D. Capra. 1991. Human immunoglobulin heavy chain variable region genes: organization, polymorphism and expression. *Adv. Immunol.* 49:1–74.
- Hexham, M., M. A. A. Persson, C. Pegg, D. R. Burton, J. Furmaniak, and B. Rees Smith. 1991. Cloning and expression of a human thyroglobulin autoantibody. *Autoimmunity*. 11:69–70.
- Portolano, S., P. Seto, G. D. Chazenbalk, Y. Nagayama, S. McLachlan, and B. Rapoport. 1991. A human fab fragment specific for thyroid peroxidase generated by cloning thyroid lymphocyte-derived immunoglobulin genes in a bacteriophage lambda library. *Biochem. Biophys. Res. Commun.* 179:372–379.
- Portolano, S., G. D. Chazenbalk, P. Seto, J. S. Hutchison, B. Rapoport, and S. M. McLachlan. 1992. Recognition by recombinant autoimmune thyroid disease-derived Fab fragments of a dominant conformational epitope on human thyroid peroxidase. *J. Clin. Invest.* 90:720–726.
- Victor, K. D., V. Pascual, A. K. Lefvert, and J. D. Capra. 1992. Human anti-acetylcholine receptor antibodies use variable gene segments analogous to those used in autoantibodies of various specificities. *Mol. Immunol.* 29:1501–1506.
- Rees Smith, B., S. M. McLachlan, and J. Furmaniak. 1988. Autoantibodies to the thyrotropin receptor. *Endocr. Rev.* 9:106–121.
- Fukuma, N., V. B. Petersen, S. M. McLachlan, C. A. S. Pegg, and B. Rees Smith. 1991. Human monoclonal thyroglobulin autoantibodies of high affinity. I. Production, characterisation and interaction with murine monoclonal thyroglobulin antibodies. *Autoimmunity*. 10:291–295.
- Han, J. H., C. Stratowa, and W. J. Rutter. 1987. Isolation of full-length putative rat lysophospholipase methods for mRNA isolation and cDNA cloning. *Biochemistry*. 26:1617–1625.
- Persson, M. A. A., R. H. Caothien, and D. R. Burton. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. *Proc. Natl. Acad. Sci. USA*. 88:2432–2436.
- Marks, J. D., M. Tristem, A. Karpas, and G. Winter. 1991. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. *Eur. J. Immunol.* 21:985–991.
- Takahashi, N., S. Ueda, M. Obata, T. Nikaido, S. Nakai, and T. Honjo. 1982. Structure of human immunoglobulin gamma genes: implications for evolution of a gene family. *Cell*. 29:671–679.
- Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Foti, D., K. D. Kaufman, G. Chazenbalk, and B. Rapoport. 1990. Generation of a biologically-active, secreted form of human thyroid peroxidase by site-directed mutagenesis. *Mol. Endocrinol.* 4:786–791.
- Salacinski, P. R. P., C. McLean, J. E. C. Sykes, V. V. Clement-Jones, and P. J. Lowry. 1981. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl Glycoluril (Iodogen). *Anal. Biochem.* 117:136–146.
- Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. *Proc. Natl. Acad. Sci. USA*. 74:5463–5467.
- Scatchard, G. 1949. The attractions of proteins for small molecules and ions. *Ann. NY Acad. Sci.* 51:660–672.
- Schardt, C. W., S. M. McLachlan, J. Matheson, and B. Rees Smith. 1982. An enzyme-linked immunoassay for thyroid microsomal antibodies. *J. Immunol. Methods* 55:155–168.
- Weetman, A. P., C. M. Black, S. B. Cohen, R. Tomlinson, J. P. Banga, and C. B. Reimer. 1989. Affinity purification of IgG subclasses and the distribution of thyroid auto-antibody reactivity in Hashimoto's thyroiditis. *Scand. J. Immunol.* 30:73–82.
- Portolano, S., G. D. Chazenbalk, J. S. Hutchison, S. M. McLachlan, and B. Rapoport. 1993. Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain "roulette." *J. Immunol.* 150:880–887.
- Tomlinson, I. A., G. Walter, J. D. Marks, M. B. Llewellyn, and G. Winter. 1992. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. *J. Mol. Biol.* 227:776–798.
- Pargent, W., A. Meindl, R. Thiebs, S. Mittel, and H. G. Zachau. 1991. The human immunoglobulin k locus: characterization of the duplicated 0 regions. *Eur. J. Immunol.* 21:1821–1827.
- Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. *Sequences of Proteins of Immunological Interest*. NIH Publication No. 91-3242. U. S. Department of Health and Human Services, Bethesda, MD.
- Olee, T., E. W. Lu, D.-F. Huang, R. W. Soto-Gil, M. Deftos, F. Kozin, D. A. Carson, and P. P. Chen. 1992. Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response. *J. Exp. Med.* 175:8310–842.
- Shin, E. K., F. Matsuda, H. Nagaoka, Y. Fukita, T. Imai, K. Yokoyama, E. Soeda, and T. Honjo. 1991. Physical map of the 3' region of the human immunoglobulin heavy chain locus: clustering of autoantibody-related variable segments in one haplotype. *EMBO (Eur. Mol. Biol. Organ.) J.* 10:3641–3645.
- Berman, J. E., S. J. Mellis, R. Pollock, C. L. Smith, H. Suh, B. Heinke, C. Kowal, U. Surti, L. Chess, C. R. Cantor, et al. 1988. Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus. *EMBO (Eur. Mol. Biol. Organ.) J.* 7:727–738.
- Chen, P. P., M. F. Liu, C. A. Glass, S. Sinha, T. J. Kippes, and D. A. Carson. 1989. Characterization of two immunoglobulin VH genes that are homologous to human rheumatoid factors. *Arth. Rheum.* 32:72–76.
- Phillips, D., S. McLachlan, A. Stephenson, D. Roberts, S. Moffitt, D.

- McDonald, A. Ad'Hiah, A. Stratton, E. Young, F. Clark, et al. 1990. Autosomal dominant transmission of autoantibodies to thyroglobulin and thyroid peroxidase. *J. Clin. Endocrinol. Metab.* 70:742-746.
35. Phillips, D., L. Prentice, M. Upadhyaya, P. Lunt, S. Chamberlain, D. F. Roberts, S. McLachlan, and B. Rees Smith. 1991. Autosomal dominant inheritance of autoantibodies to thyroid peroxidase and thyroglobulin: studies in families not selected for autoimmune thyroid disease. *J. Clin. Endocrinol. Metab.* 72:973-975.
36. Olee, T., P.-M. Yang, K. A. Siminovich, N. J. Olsen, J. Hillson, J. Wu, F. Kozin, D. A. Carson, and P. P. Chen. 1991. Molecular basis of an autoantibody-associated restriction fragment length polymorphism that confers susceptibility to autoimmune diseases. *J. Clin. Invest.* 88:193-203.
37. Casali, P., G. Inghirami, N. Nakamura, T. F. Davies, and A. L. Notkins. 1986. Human monoclonals from antigen-specific selection of B lymphocytes and transformation with EBV. *Science (Wash. DC)*. 234:476-479.
38. Sanz, I., P. Casali, J. W. Thomas, A. L. Notkins, and J. D. Capra. 1989. Nucleotide sequences of eight human natural autoantibody VH regions reveals apparent restricted use of VH families. *J. Immunol.* 142:4054-4061.
39. Weisbart, R. H., A. L. Wong, D. Noritake, A. Kacena, G. Chan, C. Ru-land, E. Chin, I. S. Y. Chen, and J. D. Rosenblatt. 1991. The rheumatoid factor reactivity of a human IgG monoclonal autoantibody is encoded by a variant VKII L chain gene. *J. Immunol. Methods*. 147:2795-2801.
40. Manheimer-Lory, A. J., J. B. Katz, M. Pillinger, C. Ghossein, A. Smith, and B. Diamond. 1991. Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype. *J. Exp. Med.* 174:1639-1652.
41. Van Es, J. H., F. H. J. Gmelig, W. R. M. van de Akker, H. Aanstoot, R. H. W. M. Derksen, and T. Logtenberg. 1991. Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. *J. Exp. Med.* 173:461-470.
42. Randen, I., D. Brown, K. M. Thompson, N. Hughes-Jones, V. Pascual, K. Victor, J. D. Capra, O. Forre, and J. B. Natvig. 1992. Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. *J. Immunol.* 148:3296-3301.
43. Martin, A., and T. F. Davies. 1992. T cells and human autoimmune thyroid disease: emerging data show lack of need to invoke suppressor T cell problems. *Thyroid*. 2:247-261.
44. Pascual, V., and J. D. Capra. 1992. VH4-21, a human VH gene segment overrepresented in the autoimmune repertoire. *Arthritis Rheum.* 35:11-18.
45. Mullinax, R. L., E. A. Gross, J. R. Amberg, B. N. Hay, H. H. Hogrefe, M. M. Kubitz, A. Greener, M. Alting-Mees, D. Ardourel, J. M. Short, et al. 1990. Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunorepression library. *Proc. Natl. Acad. Sci. USA*. 87:8095-8099.
46. Gherardi, E., and C. Milstein. 1992. Original and artificial antibodies. *Nature (Lond.)*. 357:201-202.
47. Burton, D. R., and C. F. Barbas. 1992. Antibodies from libraries. *Nature (Lond.)*. 359:782-783.
48. Caton, A. J., and H. Koprowski. 1990. Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. *Proc. Natl. Acad. Sci. USA*. 87:6450-6454.
49. Gardas, A., and H. Domek. 1988. The effect of sulphhydryl reagents on the human thyroid microsomal antigen. *J. Endocrinol. Invest.* 11:385-388.
50. Nakajima, Y., R. D. Howells, C. Pegg, E. Davies Jones, and B. Rees Smith. 1987. Structure activity analysis of microsomal antigen/thyroid peroxidase. *Mol. Cell. Endocrinol.* 53:15-23.
51. Laing, P. 1986. Antigen binding characteristics of thyroid microsomal autoantibodies studied with ELISA methods. *J. Clin. Lab. Immunol.* 19:19-23.
52. Ruf, J., M. Toubert, B. Czarnocka, J. Durand-Gorde, M. Ferrand, and P. Carayon. 1989. Relationship between immunological structure and biochemical properties of human thyroid peroxidase. *Endocrinology*. 125:1211-1218.
53. Nye, L., L. C. Pontes de Carvalho, and I. M. Roitt. 1980. Restrictions in the response to autologous thyroglobulin in the human. *Clin. Exp. Immunol.* 41:252-263.
54. Magnusson, R., G. Chazenbalk, J. Gestautas, P. Seto, S. Filetti, and B. Rapoport. 1987. Sequences of interest: molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. *Mol. Endocrinol.* 1:856-861.
55. Davies, D. R., and E. Padlan. 1990. Antibody-antigen complexes. *Annu. Rev. Biochem.* 59:439-473.
56. Frorath, B., C. C. Abney, M. Scanarini, H. Berthold, N. Hunt, and W. Northemann. 1992. Mapping of a linear autoantigenic epitope within the human thyroid peroxidase using recombinant DNA techniques. *J. Biochem.* 111:633-637.
57. Lucas, A. H., and D. M. Granoff. 1990. A major crossreactive idiotype associated with human antibodies to the *Haemophilus influenzae* b polysaccharide: expression in relation to age and immunoglobulin G subclass. *J. Clin. Invest.* 85:1158-1166.
58. Shlomchik, M. J., A. Marshak-Rothstein, C. B. Wolfowicz, T. L. Rothstein, and M. G. Weigert. 1987. The role of clonal selection and somatic mutation in autoimmunity. *Nature (Lond.)*. 328:805-811.
59. O'Keefe, T. L., S. Bandyopadhyay, S. K. Datta, and T. Imanishi-Kari. 1990. V region sequences of an idiotypically connected family of pathogenic anti-DNA autoantibodies. *J. Immunol.* 144:4275-4283.
60. Eilat, D., and R. Fischel. 1991. Recurrent utilization of genetic elements in V regions of antinuclear acid antibodies from autoimmune mice. *J. Immunol.* 147:361-368.
61. Panosian-Sahakian, N., J. L. Klotz, F. Ebling, M. Kronenberg, and B. Hahn. 1989. Diversity of Ig V gene segments found in anti-DNA autoantibodies from a single (NZB x NZW)F1 mouse. *J. Immunol.* 142:4500-4506.
62. Pascual, V., K. Victor, I. Randen, K. Thompson, M. Steinitz, O. Forres, S.-M. Fu, J. B. Natvig, and J. D. Capra. 1992. Nucleotide sequence analysis of rheumatoid factors and polyreactive antibodies derived from patients with rheumatoid arthritis reveals diverse use of VH and VL gene segments and extensive variability in CDR-3. *Scand. J. Immunol.* 36:349-362.
63. Gleason, S. L., P. Gearhart, N. R. Rose, and R. C. Kupperts. 1990. Autoantibodies to thyroglobulin are encoded by V-gene segments and recognize restricted epitopes. *J. Immunol.* 145:1768-1775.